Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled 52-week study of seladelpar in primary biliary cholangitis with inadequate response or intolerance to UDCA
MOH_2018-11-12_004753Phase 3Completed
- Sponsor
- CymaBay Therapeutics, Inc
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of seladelpar in primary biliary cholangitis (PBC) (3 arms), sponsored by CymaBay Therapeutics, Inc. Primary endpoint: Safety and effect on cholestasis over 52 weeks. Started Oct 2018; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2018-11-12_004753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-12_004753.